Publications by Program Trainees

Grant Cycle III (2014-2018)

  1. Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7. PMID: 25600186; PMCID: PMC4430366.
  2. Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC. A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling. Prostate. 76(14):1303-11; 2016. PMID: 27324988.
  3. Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. Eur Urol. 69(6):992-5; 2016. PMCID: PMC4909531.
  4. Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget. 2014 Oct 30;5(20):9939-51. PMID: 25301725. PMCID: PMC4259449
  5. Geybels MS, Neuhouser ML, Wright JL, Stott-Miller M, Stanford JL. Coffee and tea consumption in relation to prostate cancer prognosis. Cancer Causes Control. 2013 Nov;24(11):1947-54. PMID:23907772; PMCID: PMC3859380.
  6. Hempelmann JA, Scroggins SM, Pritchard CC, Salipante SJ. MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing. J Mol Diagn. 17(6):705-14; 2015. PMID: 26322950.
  7. Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS. DNA Repair in Prostate Cancer: Biology and Clinical Implications. Eur Urol. pii: S0302-2838(16)30504-8; 2016. PMID: 27590317.
  8. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 375(5):443-53; 2016. PMCID: PMC4986616.
  9. Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, Tait JF, Corey E, Vessella RL, Walsh T, Shendure J, Nelson PS. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun. 25;5:4988; 2015. PMCID: PMC4176888.
  10. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem. 60(9):1192-9; 2014. PMID: 24987110.
  11. Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC. Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget. 7(50):82504-82510; 2016. PMID: 27756888.
  12. Stott-Miller M, Wright JL, Stanford JL. MSMB gene variant alters the association between prostate cancer and number of sexual partners. Prostate. 2013 Dec;73(16):1803-9. PMID: 24037734; PMCID: PMC3992835.
  13. Stott-Miller M, Zhao S, Wright JL, Kolb S, Bibikova M, Klotzle B, Ostrander EA, Fan JB, Feng Z, Stanford JL. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1331-9. PMID: 24718283. PMCID: PMC4082437
  14. Van Allen EM, Robinson D, Morrissey C, Pritchard C, Imamovic A, Carter S, Rosenberg M, McKenna A, Wu YM, Cao X, Chinnaiyan A, Garraway L, Nelson PS. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget. 7(33):52888-52899; 2016. PMID: 27167109.
  15. Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. JAMA Oncol. 2(12):1598-1606; 2016. PMCID: PMC5097690.

Grant Cycle II (2007-2013)

Publications – Year 10

  1. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20;44(6):685-9.
  2. Barnett CM, Heinrich MC, Lim J, Nelson D, Beadling C, Warrick A, Neff T, Higano CS, Garzotto M, Qian D, Corless CL, Thomas GV, Beer TM. Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. Clin Cancer Res. 2014 Mar 1;20(5):1306-12. Epub 2013 Dec 18. PMCID: PMC3947466
  3. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One. 2013 Jul 30;8(7):e69239. PMCID: PMC3728349
  4. Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng HW, Haegert A, Bell RH, Brahmbhatt S, Anderson S, Fazli L, Hurtado-Coll A, Rubin MA, Demicheli F, Beltran H, Hirst M, Marra M, Gleave M, Lubin M, Wang Y. Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenine Phosphorylase (MTAP), an Exploitable Tumor Target. Mol Cancer Ther. 2012 Mar;11(3):775-83. Epub 2012 Jan 17.
  5. Economos C, Morrissey C, Vessella RL. Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents. Curr Opin Urol. 2012 May;22(3):190-6. Review.
  6. FitzGerald LM, Kwon EM, Conomos MP, Kolb S, Holt SK, Levine D, Feng Z, Ostrander EA, Stanford JL. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1196-203. PMCID: PMC3111761
  7. FitzGerald LM, Zhang X, Kolb S, Kwon EM, Liew YC, Hurtado-Coll A, Knudsen BS, Ostrander EA, Stanford JL.  Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum Mutat 2012 Aug 7. doi: 10.1002/humu.22176. [Epub ahead of print].
  8. Geybels MS, Wright JL, Holt SK, Kolb S, Feng Z, Stanford JL. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate. 2013 Aug;73(11):1214-22. Epub 2013 Apr 30. PMCID: PMC3967507
  9. Gore JL, Wright JL, Daratha KB, Roberts KP, Lin DW, Wessells H, Porter M. Hospital-level variation in the quality of urologic cancer surgery. Cancer. 2011 Jul 26. doi: 10.1002/cncr.26373. http://onlinelibrary.wiley.com/doi/10.1002/cncr.26373/pdf
  10. Gore J, Wright J, Daratha K, Roberts K, Lin D, Wessells H, Porter M. Hospital-Level Variation in the Quality of Urologic Cancer Surgery. Cancer. February 2012; 118(4): 987-96. PMCID: PMC3273633
  11. Gulati R, Mariotto A, Chen S, Gore J, Etzioni R. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. Journal of Clinical Epidemiology. December 2011; 64(12): 1412-7.
  12. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013 Oct;37(5):666-70. PMCID: PMC3864767
  13. Holt SK, Kwon EM, Fu R, Feng Z, Ostrander EA, Stanford JL. Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate 2012 May 1. doi: 10.1002/pros.22534. [Epub ahead of print]
  14. Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright, Camp NJ, Terrlink CC, FitzGerald LM, Stanford JL, et al. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: Evidence from the International Consortium for Prostate Cancer Genetics (ICPCG).  Human Genet 2012;131:1095-103.
  15. Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL, Ostrander EA.  Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.  Cancer Epidemiol 2012 Aug;36(4):347-53. PMCID: PMC3392409
  16. Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ, Nickerson DA, Corey E, Lange PH, Morrissey C, Vessella RL, Nelson PS, Shendure J. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17087-92. PMCID: PMC3193229
  17. Kumar A, Shendure J, Nelson PS. Genome interrupted: sequencing of prostate cancer reveals the importance of chromosomal rearrangements. Genome Med. 2011 Apr 19;3(4):23. PMC3129639
  18. Hayashi N, Peacock JW, Beraldi E, Zoubeidi A, Gleave ME, Ong CJ. Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. Cell Death Differ. 2012 Jun;19(6):990-1002. doi: 10.1038/cdd.2011.184. PMC3354053
  19. Kumano M, Furukawa J, Shiota M, Zardan A, Zhang F, Beraldi E, Wiedmann RM, Fazli L, Zoubeidi A, Gleave ME. Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer. Mol Cancer Ther. 2012 Aug;11(8):1661-71. Epub 2012 Jun 6.
  20. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, Zoubeidi A. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res. 2011 Apr 15;17(8):2301-13.
  21. Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, Zoubeidi A, Gleave ME. Clusterin Inhibition using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate Resistant Prostate Cancer. Cancer Res. 2011 Jul 7. [Epub ahead of print] http://cancerres.aacrjournals.org/content/early/2011/07/06/0008-5472.CAN-11-0994.long
  22. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado-Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC. (2012) From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. Jul;227(3):286-97. doi: 10.1002/path.4047.
  23. Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Grönberg H, Stanford JL. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.  Cancer Epidemiol Biom Prev 2011;20 (9):1928-36. PMCID: PMC3169727
  24. Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS. Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. 2011 Jun;2(3):145-56. http://www.springerlink.com/content/b6466638877n41h8/
  25. Mo F, Wyatt AW, Wu C, Lapuk AV, Marra MA, Gleave ME, Volik SV, Collins CC. Next generation sequencing of prostate tumours provides independent evidence of XMRV contamination. J Clin Microbiol. 2012 Feb;50(2):536-7. Epub 2011 Dec 7. PMCID: PMC3264157
  26. Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration resistant prostate cancer: results from the University of Washington rapid autopsy series. J Bone Miner Res. 2012 Aug 30. doi: 10.1002/jbmr.1749. [Epub ahead of print]
  27. Mostaghel EA, Lin DW, Amory JK, Wright JL, Marck BT, Nelson PS, Matsumoto AM, Bremner WJ, Page ST. Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab. 2012 Aug;97(8):2809-17. Epub 2012 Jun 1. PMCID: PMC3410271
  28. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012 Apr 18;13(5):358-69. Review. PMID: 22510765
  29. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012 Mar;5(3):492-7. Epub 2011 Dec 12. PMID:22158052
  30. Saraon P, Musrap N, Cretu D, Karagiannis GS, Batruch I, Smith C, Drabovich AP, Trudel D, van der Kwast T, Morrissey C, Jarvi KA, Diamandis EP. Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castrate-resistant prostate cancer. J Biol Chem. 2012 Aug 20. [Epub ahead of print]
  31. So AI. HIFU ablation is not a proven standard treatment for localized prostate cancer. Can Urol Assoc J. 2011 Dec;5(6):424-6. doi: 10.5489/cuaj.11232.
  32. Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, Keller ET, Hall CL. Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis. Clin Exp Metastasis. 2013 Jun;30(5):569-78. Epub 2012 Dec 15. PMCID: PMC3736758
  33. Tretiakova M, Antic T, Binder D, Kocherginsky M, Liao C, Taxy JB, Oto A. Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays. Hum Pathol. 2013 Apr;44(4):495-502.
  34. Wright JL, Lin DW, Stanford JL. Circumcision and risk of prostate cancer.  Cancer 2012 Sep 15;118(18):4437-43. PMCID: PMC3376675
  35. Wright JL, Neuhouser ML, Lin DW, Kwon EM, Feng Z, Ostrander EA, Stanford JL.  AMACR polymorphisms, dietary intake and prostate cancer risk. The Prostate 2011 Apr;71(5):498-506. PMCID: PMC3148811
  36. Wright JL, Plymate SR, Porter MP, Gore JL, Lin DW, Hu E, Zeliadt SB. Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013 Jun;16(2):204-8. Epub 2013 Mar 5. PMCID: PMC3753020
  37. Wu C, Wyatt AW, Lapuk AV, McPherson A, McConeghy BJ, Bell RH, Anderson S, Haegert A, Brahmbhatt S, Shukin R, Mo F, Li E, Fazli L, Hurtado-Coll A, Jones EC, Butterfield YS, Hach F, Hormozdiari F, Hajiresouliha I, Boutros PC, Bristow RG, Jones SJM, Hirst M, Marra MA, Maher CA, Chinnaiyan AM, Sahinalp SC, Gleave ME, Volik SV, Collins CC. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol. 2012 May;227(1):53-61. doi: 10.1002/path.3987. Epub 2012 Mar 21
  38. Xia J, Trock B, Cooperberg M, Gulati R, Zeliadt S, Gore J, Lin D, Carroll P, Carter H, Etzioni R. Prostate Cancer Mortality Following Active Surveillance Versus Immediate Radical Prostatectomy. Clinical Cancer Research. (In press)
  39. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012 Dec 14;338(6113):1465-9. PMCID: PMC3625962
  40. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011;6(11):e27970. PMCID: PMC3219707
  41. Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol. 2012 Oct;44(10):1646-56. Epub 2012 May 6. PMID: 22571949

Publications – Year 9

  1. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS, Nelson PS, Vessella RL, Trask BJ. Comparative Analyses of Chromosome Alterations in Soft-Tissue Metastases within and across Patients with Castration-Resistant Prostate Cancer. Cancer Res 69:7793-802, 2009. PMCID: PMC2771763
  2. FitzGerald LM, McDonnell SK, Carlson EE, Langeberg W, McIntosh LM, Deutsch K, Ostrander EA, Schaid DJ, Stanford JL. Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11-q14. Eur J Hum Gen 2010 Oct;18(10):1141-7. PMCID: PMC2921483
  3. Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res 70:3239-48; 2010. PMCID: PMC2999007
  4. Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL. Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate. 2010 Jun 15;70(9):1012-9. PMCID: PMC2875316
  5. Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, Peters U, Stanford JL. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate. 2010 Sep 15;70(13):1448-60. PMCID: PMC2927712
  6. Johanneson B, McDonnell SK, Karyadi DM, Quignon P, McIntosh L, Riska SM, FitzGerald LM, Johnson G, Deutsch K, Williams G, Tillmans LS, Stanford JL, Schaid DJ, Thibodeau SN, Ostrander EA. Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. Hum Mol Genet. 2010 Oct 1;19(19):3852-62. PMCID: PMC2935853
  7. Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochem Biophys Acta 1805:17-24; 2010. http://www.sciencedirect.com/science/article/pii/S0304419X09000584
  8. Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 70:239-51, 2010. http://onlinelibrary.wiley.com/doi/10.1002/pros.21057/pdf
  9. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia 12:192-205; 2010. PMCID: PMC2814357
  10. Morrissey C, Dowell A, Koreckij TD, Nguyen H, Fanslow WC, True L, Corey E, Vessella RL. Inhibition of Angiopoietin-2 in LuCaP 23.1 Prostate Cancer Tumors Decreases Tumor Growth and Viability. Prostate. 2010 Dec 1;70(16):1799-808. PMCID: PMC3104406
  11. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs. 21:423-32; 2010. PMCID: PMC2953769
  12. Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS, Vessella RL. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 70:412-24; 2010.
  13. Mostaghel EA, Wright JL, Montgomery B, Stanford JL. Response to Letter to the Editor. Cancer Epidemiol Biomarkers Prev. 2011 Aug 9. [Epub ahead of print]. http://cebp.aacrjournals.org/content/early/2011/08/05/1055-9965.EPI-11-0694.long
  14. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS, Matsumoto AM. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab. 2011 Feb;96(2):430-7. PMCID: PMC3048323
  15. Porter MP, Gore JL, Wright JL. Hospital volume and 90-day mortality risk after radical cystectomy: a population-based cohort study. World J Urol. 2011 Feb;29(1):73-7. http://www.springerlink.com/content/t31512275580k345/
  16. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol. 2011 Jul;179(1):400-10. http://www.journals.elsevierhealth.com/periodicals/ajpa/article/S0002-9440(11)00352-X/pdf
  17. Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 70:433-42; 2010. PMCID: PMC2931415
  18. Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U and Stanford JL. Use of aspirin and other non-steroidal anti-inflammatory medications in relation to prostate cancer risk. Am J Epidemiol. 2010 Sep 1;172(5):578-90. PMCID: PMC2950822
  19. Schayek H, Bentov I, Rotem I, Pasmanik-Chor M, Ginsberg D, Plymate SR, Werner H. Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Growth Horm IGF Res 20:68-72; 2010. http://www.sciencedirect.com/science/article/pii/S1096637409001142
  20. Schayek H, Bentov I, Sun S, Plymate SR, Werner H. Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res. 2010 May 15;316(9):1479-88. PMCID: PMC2873092
  21. Tavassoli P, Wafa LA, Cheng H, Zoubeidi A, Fazli L, Gleave ME, Snoek R, Rennie PS. TATA binding protein-associated factor 1 (TAF1) binds and differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin activating and conjugating domains. Mol Endocrinol 24:696-708; 2010. http://mend.endojournals.org/content/24/4/696.long
  22. Thomas C, Zoubeidi A, Kuruma H, Fazli L, Lamoureux F, Beraldi E, Monia BP, MacLeod AR, Thüroff JW, Gleave ME. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther. 2011 Feb;10(2):347-59. http://mct.aacrjournals.org/content/10/2/347.long
  23. Wright JL, Kwon EM, Lin DW, Kolb S, Feng Z, Koopmeiners J, Ostrander EA, Stanford JL. CYP17 polymorphisms and prostate cancer mortality. The Prostate, 2010 Jul 1;70(10):1094-101. PMCID: PMC2878282
  24. Wright JL, Page S, Lin DW, Stanford JL. Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiology 34:131-5; 2010. PMCID: PMC2911123
  25. Wright JL, Dalkin BL, True LD, Stanford JL, Lange PH, Lin DW. Positive surgical margins at radical prostatectomy predictprostate cancer-specific mortality. J Urology 2010 Jun;183(6):2213-8. PMCID: PMC2903223
  26. Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):619-27. PMCID: PMC3073610
  27. Wright JL, Lin DW, Stanford JL. The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate. 2011 Mar 22. doi: 10.1002/pros.21380. [Epub ahead of print]. http://onlinelibrary.wiley.com/doi/10.1002/pros.21380/pdf
  28. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011 Mar 16;103(6):520-3. http://jnci.oxfordjournals.org/content/103/6/520.long
  29. Zhau HE, He H, Wang CY, Zayzafoon M, Morrissey C, Vessella RL, Marshall FF, Chung LW, Wang R. Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells. Clin Cancer Res. 2011 Apr 15;17(8):2159-69. PMCID: PMC3085118
  30. Zhu Y, Stevens RG, Hoffman AE, FitzGerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 69:9315-22; 2009. PMCID: PMC2955869
  31. Zoubeidi A, Chi K, Gleave M. Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer. Clinical Cancer Res 16:1088-1093, 2010. 93 PMCID: PMC2822877
  32. Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LWJ, Nelson CC, Rennie PS, Gleave ME. Clusterin facilitates COMMD1 and IκB degradation to enhance NF-κB activity in prostate cancer cells. Molecular Cancer Res 8:119-30; 2010. PMCID: PMC2808437
  33. Zoubeidi A, Zardan A, Wiedmann R, Locke J, Beraldi E, Fazli L, Gleave M. Hsp27 promotes IGF-1 survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 70:2307-17; 2010. http://cancerres.aacrjournals.org/content/70/6/2307.long

Publications – Year 8

  1. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, et al. UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons’ Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF.  Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009 Oct;41(10):1116-21. PMCID: PMC2846760
  2. Zhu Y, Stevens RG, Hoffman AE, FitzGerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 2009 Dec 15;69(24):9315-22. NIHMSID: NIHMS152966
  3. FitzGerald LM, McDonnell SK, Carlson EE, Langeberg W, McIntosh LM, Deutsch K,  Ostrander EA, Schaid DJ, Stanford JL. Genome-wide linkage analyses of hereditary prostate cancer families with colon cancer provide further evidence for a susceptibility locus on 15q11-q14. Eur J Hum Gen 2010 April 21 [epub ahead of print]. NIHMSID: NIHMS186811
  4. Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U and Stanford JL. Use of aspirin and other non-steroidal anti-inflammatory medications in relation to prostate cancer risk. (submitted)
  5. Johanneson B, McDonnell SK, Karyadi DM, Quignon P, McIntosh L, Riska SM, FitzGerald LM, Johnson G, Deutsch K, Williams G, Tillmans LS, Stanford JL, Schaid DJ, Thibodeau SN, Ostrander EA. Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. (submitted)
  6. Gore J, Litwin M. Quality of care in bladder cancer: trends in urinary diversion following radical cystectomy. World J Urol. February 2009; 27(1): 45–50. PMCID: PMC2710376
  7. Gore J, Lai J, Setodji C, Litwin M, Saigal C, the Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer. March 2009; 115(5): 988–96. PMCID: PMC2654713
  8. Gore J, Kwan L, Lee S, Reiter R, Litwin M. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. June 2009; 101(12): 888–92.
  9. Lamoureux F, Picarda G, Garrigue-Antar L, Baud’huin M, Trichet V, Vidal A, Miot-Noirault E,  Pitard B, Heymann D, Rédini F. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res. 2009 Jan 15;69(2):526-36.
  10. Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochem Biophys Acta. 2010 Jan;1805(1):17-24. [Epub 2009 Sep 3]
  11. Picarda G., Lamoureux F., Geffroy L., Delepine P., Montier T., Laud K., Tirode F., Delattre O., Heymann D., Rédini F. Preclinical evidence that use TRAIL in Ewing’s sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis and increases animal survival. Clin Cancer Res. 2010 Apr 15;16(8):2363-74. PMC Journal – In Process
  12. Odri G.A., Dumoucel S, Picarda G., Battaglia S., Lamoureux F., Corradini N., Rousseau J., Tirode F., Laud K., Delattre O., Gouin F., Heymann D., Redini F. Zoledronic acid as new adjuvant therapeutic strategy for Ewing’s sarcoma patient. Cancer Res 2010 (revision submitted)
  13. Lee YS, Li N, Shin S, Jun HS. Role of nitric oxide in the pathogenesis of encephalomyocarditis viruse induced Diabetes in Mice. J Virol. 2009 Aug;83(16):8004-11. PMCID: PMC2715779
  14. Meng J, Mostaghel EA, Marks LS, True L, Nelson PS. Testosterone Regulates Tight Junction Proteins in Prostatic Epithelium: Associations with Inflammation and Aging-Related Androgen Deficiency (submitted).
  15. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS, Nelson PS, Vessella RL, Trask BJ. Comparative Analyses of Chromosome Alterations in Soft-Tissue Metastases within and across Patients with Castration-Resistant Prostate Cancer. Cancer Res. 2009 Oct 1;69(19):7793-802. PMCID: PMC2771763
  16. Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS, Vessella RL. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate. 2010 Mar 1;70(4):412-24.
  17. Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia. 2010 Feb;12(2):192-205. PMCID: PMC2814357
  18. Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T. Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs. 2010 Apr;21(4):423-32. PMC Journal – In Process
  19. Morrissey C, Dowell A, Koreckij TD, Nguyen H, Fanslow WC, True L, Corey E, Vessella RL. Inhibition of Angiopoietin-2 in LuCaP 23.1 Prostate Cancer Tumors Decreases Tumor Growth and Viability. Prostate. 2010. (submitted)
  20. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17910-5. PMCID:PMC2764905.
  21. Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res. 2010 Apr 15;70(8):3239-48.
  22. Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate. 2010 Mar 1;70(4):433-42.
  23. Schayek H, Bentov I, Sun S, Plymate SR, Werner H. Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene. Exp Cell Res. 2010 Mar 23. [Epub ahead of print] NIHMSID: NIHMS191782
  24. Schayek H, Bentov I, Rotem I, Pasmanik-Chor M, Ginsberg D, Plymate SR, Werner H. Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Growth Horm IGF Res. 2010 Feb;20(1):68-72.
  25. JL Wright, CA Salinas, DW Lin, S Kolb, J Koopmeiners, Z Feng, JL Stanford.  Differences in prostate cancer-specific mortality between cases with Gleason 4+3 and Gleason 3+4 tumors in a population-based cohort.  J Urol 2009 Dec;182(6):2702-2707.  PMCID: PMC2828768
  26. JL Wright, JL Stanford.  Metformin use and prostate cancer in Caucasian men:  results from a population-based case-control study.  Canc Caus Cont 2009 Nov;20(9):1617-22. PMCID: PMC2767519
  27. JL Wright, DW Lin. Prostate Cancer Risk Stratification by Genotype and PSA. Nat Rev Urol 2009 Dec;6(12):641-2.
  28. JL Wright, BL Dalkin, LD True, JL Stanford, PH Lange, DW Lin.  Positive surgical margins at radical prostatectomy predictprostate cancer-specific mortality.  J Urology 2010 Apr 15. [Epub ahead of print]. NIHMS: NIHMS:176535
  29. JL Wright, EM Kwon, DW Lin, S Kolb, Z Feng, J Koopmeiners, EA Ostrander, JL Stanford.  CYP17 polymorphisms and prostate cancer mortality. Accepted for publication in The Prostate, January 2010. NIHMS: NIHMS178212
  30. JL Wright, S Page, DW Lin, JL Stanford. Early onset male pattern baldness and prostate cancer risk in a population based case-control study. Cancer Epidemiology 2010 Apr;34(2):131-5. Epub 2010 Mar 4. NIHMS: NIHMS:185486
  31. Tavassoli P, Wafa LA, Cheng H, Zoubeidi A, Fazli L, Gleave ME,  Snoek R, Rennie PS. TATA binding protein-associated factor 1 (TAF1) binds and differentially enhances androgen receptor transcriptional activity via its N-terminal kinase and ubiquitin activating and conjugating domains. Mol Endocrinol. 2010 Apr;24(4):696-708. PMC Journal – In Process
  32. Zoubeidi A, Zardan A, Wiedmann R, Locke J, Beraldi E, Fazli L, Gleave M. Hsp27 promotes IGF-1 survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res. 2010 Mar 15;70(6):2307-17.
  33. Zoubeidi A, Chi K, Gleave M. Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer.  Clinical Cancer Res. 2010 Feb 15;16 (4): 1088-1093, 2010.  93 PMCID: PMC2822877
  34. Zoubeidi A, Ettinger S, Beraldi E, Hadaschik B, Zardan A, Klomp LWJ, Nelson CC, Rennie PS, Gleave ME. Clusterin facilitates COMMD1 and IκB degradation to enhance NF-κB activity in prostate cancer cells. Molecular Cancer Res. 2010 Jan;8(1):119-30. PMCID: PMC2808437
  35. Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM, Gleave ME, Nelson CC. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 2010 Feb 15;70(3):239-51.
  36. Sun J, Lau A, Wang X, Liao TY, Zoubeidi A, Hmama Z. A Broad-Range of Recombination Cloning Vectors in Mycobacteria. Plasmid. 2009 Nov;62(3):158-65.
  37. Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG, Chevalier S. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Mol Cancer Res. 2009 Jan;7(1):142-55.

Publications – Year 7

  1. Chi, KN, Zoubeidi A, Gleave ME, Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs. 2008;19(12):1955-62. PMID:19012510
  2. FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, Stanford JL, Ostrander EA. Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis. 2009;12(2):192-7. PMID:18762813. NIHMS:71384
  3. FitzGerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Can Res. 2009 May 1;15(9):3231-7. PMCID:PMC2707085
  4. FitzGerald LM, Patterson B, Thomson R, Polanowski A, Quinn S, Brohede J, Thornton T, Challis D, Mackey DA, Dwyer T, Foote S, Hannan GN, Stankovich J, McKay JD, Dickinson JL. Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease. Eur J Hum Genet. 2009 Mar;17(3):368-77. PMID:18830231
  5. FitzGerald LM, Thomson R, Polanowski A, Patterson B, McKay JD, Stankovich J, Dickinson JL. Sequence variants of α-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population. Prostate. 2008 Sep;68(13):1373-9. PMID:18537123
  6. Harris JN, Bowen DJ, Kuniyuki A, McIntosh L, FitzGerald LM, Ostrander EA, Stanford JL. Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives. Genet Med 2009 May;11(5):344-55. PMCID:PMC2683189
  7. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev.  2009 Jun;18(6):1929-33. PMID:19454612. NIHMS:106140
  8. Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella RL, Nelson PS. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol. 2008 Jun;215(2):118-25. PMID:1833833
  9. Morrissey C and Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. Journal of Cellular Biochemistry. J Cell Biochem. 2007 Jul 1;101(4):873-86. PMID:17387734
  10. O’Sullivan J, Sheridan J, Mulcahy H, Tenniswood M, Morrissey C. The effect of green tea on oxidative damage and tumour formation in Lobund-Wistar rats. Eur J Cancer Prev. 2008 Nov;17(6):489-501. PMID:18941371
  11. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, et al. Australian Cancer Study; Australian Ovarian Cancer Study Group. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer. 2009 Jan 27;100(2):412-20. PMID:19127255
  12. Qian DZ, Huang CY, O’Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM. Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res. 2009 May 1;15(9):3135-42. PMID:19366833.
  13. Salinas CA, Koopmeiners JS, Kwon EM, FitzGerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate. 2009 Mar;69(4):363-72. PMID:19058137 NIHMS:105496
  14. Stanford JL, FitzGerald LM, McDonnell SK, Carlson EE, McIntosh LM, Deutsch K, Hood L, Ostrander EA, Schaid DJ. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet. 2009 May 15;18(10):1839-48. PMCID:PMC2671990
  15. Wright JL, DW Lin, Cowan JE, Carroll PR, Litwin MS and the CaPSURE Investigators.  Quality of life in young men after radical prostatectomy.  Prostate Cancer Prostatic Dis 2008;11(1):67-73.  PMID:17519925
  16. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenctomy and survival among patients with lymph node metastases undergoing radical cystectomy.  Cancer 2008;112(11):2401-8. PMID:18383515
  17. Wright JL, Hotaling J, Porter MP.  Upper tract transitional cell carcinoma after primary bladder cancer:  a 15 year analysis.  J Urol 2009;181(3):1035-9.  PMID:19150569
  18. Wright JL, Morgan TM, Lin DW.  Primary scrotal cancer: survival patterns and increasing incidence.  Urology 2008;72(5);1139-43. PMID:18799208

Publications –  Year 6

  1. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis.
    J Cell Biochem. 2007 Jul 1;101(4):873-86. Review.
    PMID: 17387734
  2. Morrissey C, Kostenuik PL, Brown LG, Vessella RL, Corey E. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
    BMC Cancer. 2007 Aug 3;7:148.
    PMID: 17683568
  3. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research 2007. Nov 1;67(21):10455-65.
    PMID: 17974989
  4. Sowery RD, Hadaschik BA, So A, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU 2008 Aug;102(3):389-97
    PMID: 18336596
  5. Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME, Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. Int J Cancer. 2008 May 15;122(10):2368-76.
    PMID: 18240145
  6. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clinical Cancer Research, 2008 Jun 15;14(12):3823-31.
    PMID: 18559602
  7. Holt S.K., Salinas C.A., Stanford J.L. Vasectomy and risk of prostate cancer. Journal of Urology, 2008 Dec;180(6):2565-7; discussion 2567-8
    PMID: 18930503
  8. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Wang Y, Corey E, Lange PH, Higano CS, Nelson PS, Vessella RL. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis. 2008;25(4):377-88
    PMID: 17972146
  9. Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella RL, Nelson PS. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol. 2008 Jun;215(2):118-25.
    PMID: 18338334
  10. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J. Urol. 2008 Sep;180(3):1154-60
    PMID: 18639279
  11. Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, Sadar MD, English J, Fazli L, So, A, Gout PW,  Gleave ME, Squire JA, Wang YZ. ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Research. 2008 Jun 1;68(11):4352-9.
    PMID: 18519696
  12. Narita S, So A, Ettinger S, Hayashi N,  Muramaki M, Fazli L, Kim Y, Gleave M.  GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen independent prostate cancer. Clinical Cancer Research 2008 Sep 15;14(18):5769-77
    PMID: 18794086
  13. Wu, J.D., C.L. Atteridge, X. Wang, T. Seya, S. R. Plymate. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 2009 Jan 15;15(2):632-40.
    PMID: 19147769

Grant Cycle I (2001-2006)

Publications

  1. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.  Prostate 52:20-33, 2002.
    PMID: 11992617
  2. Tiguert, R., Lessard, A., So, A., and Fradet, Y. Prognostic markers in muscle invasive bladder cancer.  World J Urol 20: 190-195, 2002.
    PMID: 12196903
  3. So, A., Hickey, L., and Norman, R. Late ureteral conduit urinary leak as a presentation of urothelial carcinoma of the ureter.  Urol 59: 946, 2002; Urol Review Journal 4: 20-21, 2003
    PMID: 12031389
  4. So, A., Goldenberg, L., and Gleave, M.E. Prostate specific antigen: an updated review. Can J Urol 10: 2040-2050, 2003.
    PMID: 14704108
  5. So, A., Hurtado-Coll, A., and Gleave, M.E. Androgens and prostate cancer. World J Urol 21: 325-327, 2003.
    PMID: 14586548
  6. So, A., and Paterson, R.F. Gross hematuria in a man with normal renal function (case review).  Renal and Urology News, 2003
  7. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 9:295-306, 2003.
    PMID: 12538482
  8. Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, Vessella RL. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.  Clin and Exp Metastasis 20:171-180, 2003
    PMID: 12705638
  9. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange PH, Vessella RL. Phenotypic  heterogeneity of end-stage prostate carcinoma metastatic to bone. Human Path. 34:646-653, 2003
    PMID: 12874759
  10. Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM. Comparison of immunohistochemistry with RT-PCR for the detection of micrometastatic prostate cancer in lymph nodes.  Cancer Res. 63:4662-4670, 2003
    PMID: 12907647
  11. Roudier MP, True LD, Vessella RL, Higano CS. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.  Journal of Clin. Path. 57:321-323, 2004
    PMID: 14990610
  12. Roudier MP, Corey E, True LD,  Higano CS, Ott SM, Vessella RL.  Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases.  Ed. E Keller and L Chung. The Biology of Skeletal Metastases, Kluwer Academic Publishers, Boston, pp 311-339, 2004.
    PMID: 15043198
  13. Cheteri, M.B., Stanford, J.L., Friedrichsen, D., Peters, M.A., Iwasaki, L., et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 59: 409-418, 2004.
    PMID: 15065089
  14. July, L.V., Beraldi, E., So, A., Evans, K., English, J., Fazli, L., and Gleave, M.E. Nucleotide-based therapies targeting clusterin chemosensitizes human lung adenocarcinoma cells both in vitro and in vivo. Molecular Cancer Therapeutics 3: 223-232, 2004
    PMID: 15026542
  15. Rocchi, P., So, A., Kojima, S., Signaevsky, M., Beraldi, E., Fazli, L., Hurtado-Coll, A., Yamanaka, K., and Gleave, M.E. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone refractory prostate cancer.  Cancer Res 64: 6595-602, 2004.
    PMID: 15374973
  16. Miyake, H., Eto, H., Hara, I., So, A., Li, D., and Gleave, M.E. Synergistic antitumor activity by combine4d treatment with Gemcitabine and anti-sense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer KoTCC-1 cells.  J Urol 171: 2477-2481, Comment 2482-3. 2004.
    PMID: 15126879
  17. So, A., Bowden, M., and Gleave, M.E. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionigi tumours. Brit J Urol.93: 845-850, 2004
    PMID: 15050003
  18. Trougakos, I., So, A., Jansen, B., Gleave, M.E., and Gonos, E.S. Silencing expression of the clusterin/apolipoprotein J gene human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64:1834-1842, 2004.
    PMID: 14996747
  19. Rocchi, P., Muracciole, X., Fina, F., Mulholland, D., Karsenty, G., Palmari, J., Bladou, F., and Martin, P.M. Molecular analsis of androgen independent progression of prostatic carcinoma in vivo LuCaP23.1 xenograft.  Oncogene 56: 9111-9119, 2004.
    PMID: 15489889
  20. Lai, J.S., Brown, L.G., True, L.D., Hawley, S.J., Etzioni, R.B., Higano, C.S., Ho, S.M., Vessella, R.L., and Corey, E. Metastases of prostate cancer express estrogen receptor-beta. Urology, 64: 814-820, 2004.
    PMID: 15491740
  21. Eigl BJC, Eggener SE, Baybik J, Ettinger J, Chi KN, Nelson C, Wang Z, Gleave ME. Timing is everything: Preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin. Cancer Res. 2005 11: 4905-4911.
    PMID: 16000589
  22. Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential.  Oncol Rep. 13: 341-345, 2005.
    PMID: 15643522
  23. Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, Hara I: Enhanced expression of the secreted form of cluserin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep. 5:1371-1375, 2005.
    PMID: 16211311
  24. Yamanaka K, Gleave M, Muramaki M, Hara I, Miyake H. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. Oncol Rep. 5: 885-90, 2005
    PMID: 15809754
  25. Yamanaka K, Gleave ME, Hara I, Muramaki M, Miyake H. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther. 2:187-195, 2005.
    PMID: 15713890
  26. Yamanaka, K., Rocchi, P., Miyake, H., Fazil, L., Vessella, R., Zangemeister-Wittke, U., and Gleave, M.E. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther. 11: 1689-1698, 2005.
    PMID: 16275990
  27. Taieb D, Malicet C, Garcia S, Rocchi P, Arnaud C, Dagorn JC, Iovanna JL, and Vasseur S.  Inactivation of the stress protein p8 increases carbon tetrachloride hepatotoxicity through alteration of CYP2E1 inhibition.  Hepathology 42: 176-182, 2005.
    PMID: 15962327
  28. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, and Gleave M.  Increased Hsp27 after androgen ablation facilitates androgen independent progression in prostate cancer via stat3-medicated suppression of apoptosis.  Cancer Res. 65: 11083-11093, 2005.
    PMID: 16322258
  29. Fina F, Muracciole X, Rocchi P, Nanni-Metellus I, Delfino C, Daniel L, Dussett C, Ouafik LH, and Martin PM. Molecular profile of androgen-independent prostate cancer xenograft LuCaP23.1.  Journal Steroid Biochem Mol Biol. 96: 355-365, 2005.
    PMID: 16043352
  30. So, A., Sinnemann, S., Huntsman, D., Fazli, L., and Gleave, M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.  Mol Cancer Ther. 4: 1837-1849, 2005.
    PMID: 16373699
  31. So, A., Rocchi, P., and Gleave, M. Antisense oligonucleotide therapy in the management of bladder cancer. Current Opinion in Urol. 15: 320-327, 2005
    PMID: 16093856
  32. So, A., Hurtado, A., Gleave, M.E., and Nelson, C. Mechanisms of the development of androgen independence in prostate cancer.  World J Urol. 2005 Feb;23(1):1-9
    PMID: 15770516
  33. Roudier, M.P., Bain, S.D., and Dougall, W.C. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.  Clin Exp Metastasis: 2006;23(3-4):167-75
    PMID: 16912914
  34. Yamanaka, K., Rocchi, P., Miyake, H., Fazil,L., So, A., Zangemeister-Wittke, U., and Gleave, M. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligoniucleotide targeting Bcl-2 and Bcl-xl genes.  British J of Urol 97: 1300-1308, 2006
    PMID: 16686729
  35. Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, Coleman I, Nelson PS. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. International Journal Cancer 114: 563-571, 2006.
    PMID: 15609334
  36. Bavik, C., Coleman I, Dean, J.P., Knudsen. B., Plymate, S., and Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Research 66: 794-802, 2006.
    PMID: 16424011
  37. Rauch, A., Bellew, M., Eng, J., Fitzgibbon, M., Holzman, T., Hussey, P., Igra, M., MacLean, B., Lin, C.W., Detter, A., Fang. R., Faca, V., Gafken, P., Zhang, H., Whiteaker, J., States, D., Hanash, S., Paulovich, A., and McIntosh, M. Computational proteomics analysis system (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 5: 112-121, 2006.
    PMID: 16396501
  38. Bellew,M., Coram, M., Fitzgibbon, M., Igra, M., Randolph,T., Wang, P., May, D., Eng, J., Fang, R., Lin, C.W., Chen, J., Goodlet, D., Whiteaker, J., Paulovich, A., and McIntosh, M.  A suite of algorithms for the comprehensive analysis of complex protein mixtures using high-resolution LC-MS. Bioinformatics 22: 1902-1909, 2006
    PMID: 16766559
  39. Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C, and Gleave M.  Small interference RNA targeting heat shock protein 27 inhibits the growth of Prostatic cell lines and induces apoptosis via cespase-3 activation in vitro.  British J of Urol. 2006 Nov;98(5):1082-9
    PMID: 16879439
  40. Agalliu, I., Lin, D.W., Salinas, C.A., Feng, Z., and  Stanford, J.L. Polymorphisms in the glutathione S-trasferase M(1), T(12), and P(1) genes and prostate cancer prognosis. Prostate 66: 1535-1541, 2006.
    PMID: 16921513
  41. Salinas, C.A., Agalliu, I., Stanford, J.L., and Lin. D.W. Statins and the risk of cancer. JAMA 295: 2721-2722, 2006.
    PMID: 16788124
  42. Agalliu, I., Langeberg, W.J., Lampe, J.W., Salinas, C.A., Lampe, J.W., Salinas, C.A., and Stanford, J.L. Glutathione S-transferase M1. T1, and P1 polymorphisms and prostate cancer risk in middle-aged men.  Prostate 66: 146-156, 2006.
    PMID: 16173036
  43. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 66: 971-86, 2006.
    PMID: 16541420
  44. True. L., Coleman, I., Hawley, S., Huang, C.Y., Gifford, D., Coleman, R., Beer, T.M., Gelmann, E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS. Related articles, Links. A molecular correlate to the Gleason grading system for  prostate adenocarcinoma. Proceedings of the National Academy of Science USA 103 (29):10991-6, 2006
    PMID: 16829574
  45. Page, S.T., Lin,D.W., Mostaghel, E.A., Hess, D.L., True, L.D., Amory, J.K., Nelson, P.S., Matsumoto, A.M., and Bremner, W.J. Persistent intraprostatic androgen concentration after medical castration in healthy men. Journal of Clinical Endocrinology and Metabolism 2006 Oct;91(10):3850-6
    PMID: 16882745
  46. Marks LS, Mazer NA, Mostaghel EA, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov D, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.  Journal of the American Medical Association. 2006 Nov 15;296(19):2351-61.
    PMID: 17105798
  47. Gong, Z., Neuhouser, M.L., Goodman, P.J., Albanes, D., Chi, C., Hsing., A.W., Lippman S.M., Platz, E.A., Pollak, M.N., Thompson, I.M., and Kristal, A.R. Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2006 Oct;15(10):1977-83.
    PMID: 17035408
  48. Gong, Z., Agalliu, I., Lin, D.W., Stanford, J.L., and Kristal, A.R. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007 Mar 15;109(6):1192-202
    PMID: 17311344
  49. Inoue, L.Y., Neira, M., Nelson, C.C., Gleave, M.E., Etzioni, R. Cluster-based Network models for time-course gene expression data. Biostatistics 2007 Jul; 8(3):507-25
    PMID: 16980695